Wellness app introduces menopause and migraine education content

The US sexual wellness app Rosy is to introduce new content focused on menopause and migraine education.

Rosy, a digital platform currently available in the US and Canada, aims to reduce the shame and stigma around women’s health and provide a multidisciplinary approach that supports women holistically.

Now, through its new sponsorship from pharmaceutical giant Pfizer, Rosy will provide women in the US with free “evidence-based” resources, rolled out in two phases.

The first will focus on menopause and the second on migraine, with the overall goal of empowering women to take their health into their own hands.

Each year, an estimated one million Americans reach menopause, which can coincide with symptoms like vaginal dryness, decreased sensation and libido, pelvic floor issues and urinary problems.

Historically, these issues have gone ignored and unaddressed, with 73 per cent of women not receiving treatment.

Through the first phase of the sponsorship from Pfizer, Rosy will aim to create a series of modules to increase awareness surrounding menopause-related topic, which will include symptoms, diagnosis, lifestyle change to support symptom relief and potential treatment options.

During phase two, the company will focus on patient awareness modules for women suffering from migraine, a leading cause of disability worldwide among young adult women.

“We’re thrilled to be building out our network and offering free educational resources to women, empowering them to confidently take action regarding important, lifetime health concerns,” said Dr Lyndsey Harper, founder and CEO of Rosy.

“Our larger goal is not just to inform women, but also provide them with personalised recommendations for evidence-based interventions to support them on their journey to optimal health.

“With continued scale, our educational modules have the ability to change not only the health of individuals but the health of larger populations as well.”

To receive the Femtech World newsletter, sign up here.